Celldex Therapeutics Inc
$ 26.03
-1.40%
29 Dec - close price
- Market Cap 1,754,266,000 USD
- Current Price $ 26.03
- High / Low $ 26.60 / 25.51
- Stock P/E N/A
- Book Value 9.01
- EPS -3.38
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.22 %
- ROE -0.32 %
- 52 Week High 30.50
- 52 Week Low 14.40
About
Celldex Therapeutics, Inc. (CLDX) is a biopharmaceutical company based in Hampton, New Jersey, focused on developing innovative therapeutic monoclonal and bispecific antibodies aimed at addressing significant unmet medical needs in oncology and neurology. Leveraging proprietary technologies to enhance the efficacy and safety of its offerings, Celldex is advancing a robust pipeline of clinical programs that positions it at the forefront of targeted biologics. As the company continues to execute its strategic initiatives, it is poised to drive transformative changes in treatment paradigms for patients confronting critical health challenges.
Analyst Target Price
$53.36
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-07 | 2025-05-05 | 2025-02-24 | 2024-10-31 | 2024-08-08 | 2024-05-06 | 2024-02-26 | 2023-11-02 | 2023-08-08 | 2023-05-04 | 2023-02-28 |
| Reported EPS | -1.01 | -0.85 | -0.81 | -0.71 | -0.64 | -0.54 | -0.56 | -0.83 | -0.81 | -0.65 | -0.62 | -0.56 |
| Estimated EPS | -0.8985 | -0.86 | -0.69 | -0.7146 | -0.67 | -0.59 | -0.69 | -0.74 | -0.68 | -0.67 | -0.63 | -0.59 |
| Surprise | -0.1115 | 0.01 | -0.12 | 0.0046 | 0.03 | 0.05 | 0.13 | -0.09 | -0.13 | 0.02 | 0.01 | 0.03 |
| Surprise Percentage | -12.4096% | 1.1628% | -17.3913% | 0.6437% | 4.4776% | 8.4746% | 18.8406% | -12.1622% | -19.1176% | 2.9851% | 1.5873% | 5.0847% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CLDX
2025-12-21 09:57:00
Barclays has increased its price target for Celldex Therapeutics (CLDX) to $24 from $21, while reaffirming an Equal Weight rating. This adjustment is part of its 2026 outlook for the biotechnology sector. Concurrently, Celldex Therapeutics initiated a global Phase 3 trial for barzolvolimab, a specialized monoclonal antibody, to evaluate its efficacy and safety in treating cold urticaria and symptomatic dermographism.
2025-12-21 09:09:52
Corient Private Wealth LLC recently acquired 201,717 shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) in the second quarter, valued at approximately $4.11 million. This makes Corient a significant new institutional holder of the biopharmaceutical company's stock, though other institutions like American Century Companies Inc. hold even larger stakes. Insider Richard M. Wright recently sold a substantial portion of his shares, while analysts have a "Moderate Buy" consensus rating with a $44.10 price target despite the company missing its last quarterly EPS estimate.
2025-12-21 06:57:00
Barclays has increased its price target for Celldex Therapeutics (CLDX) to $24 from $21, reaffirming an "Equal Weight" rating, considering its 2026 outlook for the biotechnology sector. The adjustment comes as Celldex initiated a global Phase 3 trial for barzolvolimab, a crucial drug for cold urticaria and symptomatic dermographism, which has shown promising results in earlier studies. Despite the potential, the article suggests that certain AI stocks might offer greater upside and less risk than CLDX.
2025-12-20 04:09:41
Celldex Therapeutics (CLDX) has seen a recent uptick in its share price, prompting investors to assess its valuation. Despite the recent gains, potentially indicating improving momentum, the clinical-stage biotech faces a volatile history with a negative 3-year total shareholder return. The company's price-to-book ratio of 2.8x suggests it's modestly valued compared to some peers but slightly expensive relative to the broader US biotech industry, reflecting ongoing risks such as trial setbacks and potential dilution.
2025-12-17 18:08:30
Barclays has increased its price target for Celldex Therapeutics (NASDAQ:CLDX) to $24.00, though it maintains an "underweight" rating, suggesting a potential 9.62% downside. This rating adjustment follows Celldex missing its Q3 earnings estimates and insider stock sales, even as the consensus analyst rating remains a "Moderate Buy" with an average target of $44.10. Other analysts have provided conflicting ratings, ranging from "Strong Buy" to "Sell," reflecting general mixed sentiment towards the biopharmaceutical company.
2025-12-14 05:09:10
Celldex Therapeutics, Inc. (NASDAQ:CLDX) has received a "Moderate Buy" consensus rating from eleven brokerages, with an average 12-month target price of $43.80. This sentiment comes despite the company missing Q3 earnings estimates and insider Richard M. Wright significantly reducing his stake. The stock is currently trading near its 12-month high.
